YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

Astellas

Status and phase: Terminated; Phase 2

Conditions: Hormone-Refractory Prostate Cancer; Prostatic Neoplasms

Treatments: Drug: YM598

Study type: Interventional

Funder types: Industry

Identifiers

NCT00048659

598-CL-008

Details and patient eligibility

About

The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind